Delving into the Latest Updates on Adipose stem cell therapy (Anterogen) with Synapse

Overview

Basic Info

Drug Type

Stem cell therapy

Synonyms

ADIPOPLUS

Target-

Action-

Mechanism

Cell replacements

Therapeutic Areas

Digestive System DisordersSkin and Musculoskeletal DiseasesOther Diseases

Active Indication

Rectal FistulaSubcutaneous fat disorderCicatrix

Inactive Indication

BurnsCrohn DiseaseDiabetic Foot+ [4]

Originator Organization

Anterogen Co., Ltd.

Active Organization

Anterogen Co., Ltd.

Inactive Organization-

License Organization-

Drug Highest PhaseApproved

First Approval Date

South Korea (31 Aug 2007),

Cicatrix

Regulation-

Login to view timeline

Up to date, a sure cure for Crohn's fistula does not known and the fistula recurrence rate is high. On 15 October 2008, orphan designation was granted by Korea FDA for human adipose-derived stem cell (ADIPOPLUS) for the treatment of Crohn's fistula. In this study, patients are given injection of ADIPOPLUS in fistula site and followed for 8 weeks to evaluate the safety and efficacy.

Start Date01 Feb 2010

Sponsor / Collaborator

Anterogen Co., Ltd.

NCT00992485

/ CompletedPhase 1

A Phase I Dose Escalation Clinical Study of ADIPOPLUS (Autologous Cultured Adipose-derived Stem Cell) for the Treatment of Crohn's Fistula to Evaluate Safety and Efficacy

Up to date, a sure cure for Crohn's fistula has not known and the fistula recurrence rate is high. On 15 October 2008, orphan drug designation was granted by Korea FDA to Anterogen Co. Ltd., for human adipose-derived stem cell. In this study, patients are given injection of ADIPOPLUS in fistula site and followed for 8 weeks to test the safety and efficacy.

Start Date01 Nov 2008

Sponsor / Collaborator

Anterogen Co., Ltd.

100 Clinical Results associated with Adipose stem cell therapy (Anterogen)

Login to view more data

100 Translational Medicine associated with Adipose stem cell therapy (Anterogen)

Login to view more data

100 Patents (Medical) associated with Adipose stem cell therapy (Anterogen)

Login to view more data

100 Deals associated with Adipose stem cell therapy (Anterogen)

Login to view more data

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Rectal Fistula	South Korea	Anterogen Co., Ltd.	31 Jan 2012
Subcutaneous fat disorder	South Korea	Anterogen Co., Ltd.	31 Mar 2010
Cicatrix	South Korea	Anterogen Co., Ltd.	31 Aug 2007

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Tendon Injuries	Phase 2	South Korea	Anterogen Co., Ltd.	31 Jan 2014
Burns	Phase 2	South Korea	Anterogen Co., Ltd.	-
Epidermolysis Bullosa	Phase 2	South Korea	Anterogen Co., Ltd.	-
Glomerulonephritis, IGA	Phase 2	South Korea	Anterogen Co., Ltd.	-
Osteoarthritis	Phase 2	South Korea	Anterogen Co., Ltd.	-
Crohn Disease	Phase 1	South Korea	Anterogen Co., Ltd.	09 Jan 2020
Diabetic Foot	Phase 1	South Korea	Anterogen Co., Ltd.	04 Jul 2018